Login / Signup

Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials.

Mark G LebwohlRichard Bruce WarrenHoward SofenShinichi ImafukuCarle F PaulJacek Cezary SzepietowskiLynda SpelmanThierry PasseronEleni VritzaliAndrew NapoliRenata M KisaAlex BuckSubhashis BanerjeeDiamant ThaҫiAndrew Blauvelt
Published in: The British journal of dermatology (2024)
Deucravacitinib maintained efficacy and demonstrated consistent safety with no new safety signals observed through 2 years.
Keyphrases
  • phase iii
  • open label
  • clinical trial
  • coronary artery disease
  • double blind
  • phase ii
  • placebo controlled
  • randomized controlled trial
  • atopic dermatitis